Hoerter Steven L.
CIK: 0001533451
Hoerter Steven L.'s purchase track record
Hoerter Steven L. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/17/2025 | MBX | $265K | +206.6% | +155.4% | +6.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| MBX | ▲ Buy | Grant | 71,000 | $0 | 8/3/2026 | View on chart |
| MBX | ▲ Buy | Grant | 11,938 | $0 | 5/1/2026 | View on chart |
| MBX | ▲ Buy | Open Market | 20,000 | $265K | 10/17/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MBX Biosciences to Attend Investor Conferences, Analyst Target Raised
MBX Biosciences will join several investor conferences in November, offering a chance for investors to hear about its pipeline. Stifel has kept a positive stance and lifted its target price to $84. Analysts are debating whether the recent 257% jump has pushed the stock above fair value, while others question if the pullback from a strong year run still leaves room for upside.
MBX Biosciences to Attend Investor Conferences, Analyst Target Raised. MBX Biosciences will join several investor conferences in November, offering a chance for investors to hear about its pipeline. Stifel has kept a positive stance and lifted its target price to $84. Analysts are debating whether the recent 257% jump has pushed the stock above fair value, while others question if the pullback from a strong year run still leaves room for upside.